Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in Subjects With Moderate to Sever Plaque Psoriasis of the Scap)

Trial Profile

A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in Subjects With Moderate to Sever Plaque Psoriasis of the Scap)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms STYLE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 24 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 14 Jan 2019 Planned End Date changed from 28 Dec 2018 to 9 Jan 2019.
    • 08 Oct 2018 Primary endpoint has been met. (Proportion of subjects with ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top